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Abstract
Background: Understanding of the physical, functional and psychosocial health problems and needs of cancer
survivors requires cross-national and cross-cultural standardization of health-related quality of life (HRQoL)
questionnaires that capture the full range of issues relevant to cancer survivors. To our knowledge, only one
study has investigated in a comprehensive way whether a questionnaire used to evaluate HRQoL in cancer
patients under active treatment is also reliable and valid when used among (long-term) cancer survivors. In
this study we evaluated, in an international context, the psychometrics of HRQoL questionnaires for use among
long-term, disease-free, survivors of testicular and prostate cancer.
Methods: In this cross-sectional study, we recruited long-term survivors of testicular and prostate cancer from
Northern and Southern Europe and from the United Kingdom who had participated in two phase III EORTC
clinical trials. Participants completed the SF-36 Health Survey, the EORTC QLQ-C30 questionnaire, the QLQ-PR25
(for prostate cancer) or the QLQ-TC26 (for testicular cancer) questionnaires, and the Impact of Cancer questionnaire.
Testicular cancer survivors also completed subscales from the Nordic Questionnaire for Monitoring the Age Diverse
Workforce.
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Results: Two hundred forty-two men (66% response rate) were recruited into the study. The average time since
treatment was more than 10 years. Overall, there were few missing questionnaire data, although scales related to
sexuality, satisfaction with care and relationship concerns of men without partners were missing in more than 10% of
cases. Debriefing showed that in general the questionnaires were accepted well. Many of the survivors scored at the
upper extremes of the questionnaires, resulting in floor and ceiling effects in 64% of the scales. All of the questionnaires
investigated met the threshold of 0.70 for group level reliability, with the exception of the QLQ-TC26 (mean reliability .64)
and the QLQ-PR25 (mean reliability .69). The questionnaires were able to discriminate clearly between patients with and
without comorbid conditions.
Conclusions: The currently available HRQoL questionnaires exhibit acceptable psychometric properties and were well
received by patients, but additional efforts are needed to ensure that the full range of survivor-specific issues is assessed.
Keywords: Cancer, Oncology, Prostatic neoplasms, Questionnaires, Testicular neoplasms
Background
More than half of European patients diagnosed with
cancer enjoy survival of five years or longer after pri-
mary diagnosis [1]. However, a long period of survival is
not synonymous with a life free of physical and psycho-
social health problems related to the cancer and/or its
treatment. Studies investigating health-related quality of
life (HRQoL) in long-term cancer survivors have shown
that cancer-related health concerns can persist for years
after initial treatment [2–4].
Increasing attention is being paid to the HRQoL of
long-term cancer survivors (i.e., 10 years or longer after
diagnosis) [2, 5–7]. Understanding of the physical, func-
tional and psychosocial health problems and needs of
cancer survivors requires cross-national and cross-
cultural standardization of HRQoL questionnaires that
capture the full range of issues relevant to cancer survi-
vors [8]. To our knowledge, only one previous study has
investigated in a comprehensive way whether question-
naires used to evaluate HRQoL in cancer patients under
active treatment are also reliable and valid when used
among (long-term) cancer survivors. This study ad-
dressed the psychometrics of the EORTC Prostate can-
cer module (QLQ-PR25) in a large population-based
sample from Ireland [9].
Although our ultimate goal is to identify and/or de-
velop HRQoL questionnaires relevant to a wide range of
cancer survivor populations, for this study we focused
on survivors of two important genitourinary cancers –
testicular cancer (TCa) and prostate cancer (PCa) -
treated in the context of two EORTC phase III clinical
trials [10, 11]. TCa is a disease that affects young adults.
At the turn of the current century, the cure rate for TCa
was slightly greater than 90% [12], and in the ensuing
years it has increased to 98% [13]. Prostate cancer (PCa)
is the most prevalent cancer among men in Western,
industrialized countries [14]. For men diagnosed with
local or loco-regional PCa, the relative 10 year survival
rate is 91% [15].
From previous studies we know that, although TCa sur-
vivors report a level of general HRQoL comparable to the
general population, they are confronted with a number of
specific health issues. A minority of TCa survivors experi-
ence long-term side-effects of their treatment, including
fertility problems [16–20], peripheral neuropathy, ototox-
icity, Raynaud phenomena, gastrointestinal symptoms, de-
creased pulmonary function, cardiovascular disease and
secondary tumors [17, 19, 21–23]. Also, there is evidence
of heightened levels of fatigue, anxiety, and cancer-related
distress [24–27], practical problems related to obtaining
insurance or bank loans [6, 12], and less satisfactory social
contacts with friends and acquaintances [18]. It should be
noted, that TCa survivors also report positive conse-
quences of having had cancer, including emotional
growth, greater appreciation of life, and stronger relation-
ships with family and friends [28].
As is the case for TCa survivors, PCa survivors report
equal or better overall HRQoL as compared to healthy
controls, and generally do well in terms of psycho-
logical well-being [29]. However, almost 40% of PCa
survivors expresses heightened fear of disease recur-
rence and psychological distress [5]. Further, advanced
age in (prostate) cancer survivors is associated with
worse HRQoL outcomes [30–32], and comorbidity
serves as an additional risk [33–35]. Moreover, treat-
ment of PCa can have a profound impact on urinary,
sexual and bowel function [36, 37]. These specific,
long-term HRQoL problems are, in part, treatment
dependent [31, 38–41]. Other long-term sequelae of
PCa are hypertension, cerebrovascular episodes, osteo-
porosis, and neuropathy [3, 42].
The objectives of this study were twofold: 1) to deter-
mine the feasibility of conducting HRQoL research
among long-term cancer survivors treated in EORTC
phase III clinical trials; and 2) to evaluate the psycho-
metrics of questionnaires for assessing the HRQoL of
long-term cancer survivors (>10 years disease free). In a
previous paper [43] we reported on the feasibility of and
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challenges associated with conducting HRQoL investiga-
tions among long-term cancer survivors. In the current
paper, we focus on the second objective.
Methods
Participants
Participants were long-term survivors of two European
Organisation for Research and Treatment of Cancer
(EORTC) Genito-Urinary Cancers Group phase III clin-
ical trials, with no evidence of active disease. The PCa
survivors were recruited from Trial 22911 [11] (a collab-
oration with the EORTC Radiation Oncology Group,
inclusion 1992–2001), which investigated post-surgical
(adjuvant) irradiation of the prostate surgical bed ver-
sus ‘wait and see’. We recruited survivors from the
Netherlands, Belgium, France, and Italy. Since patients
had entered this trial with a median age of 65 years, at
the time of data collection at least 50% of patients
were very elderly or had died. Therefore, we recruited four
additional patients aged 65–75 years, who were not part
of this trial but received the same treatment from the
clinics that were included in this clinical trial.
The TCa survivors were recruited from Trial 30941/
MRC TE20 [10], which investigated different regimen of
bleomycin, etoposide, and cisplatin (BEP) (inclusion
1995–1998). We recruited survivors from the Netherlands,
Italy, Norway, and the United Kingdom. Since this trial
included only six Southern European survivors, 37 add-
itional survivors, treated according to the same regimen
(three cycles of BEP over 5 days), were recruited from Italy
outside of the trial.
We believe that it was important to supplement our
sample to compensate for the underrepresentation of
certain subgroups in the available clinical trial samples
(i.e., those aged 65–75 years in the case of PCa, and
those from Southern Europe in the case of TCa).
There is no reason to believe that the inclusion of
these additional patients in the study sample would in-
fluence the psychometric properties of the question-
naires under investigation. They were all long-term
survivors as well.
Study design
Eligible survivors received an invitation letter signed by
their treating physician, an informed consent form and
the questionnaire battery. A reminder was sent after
three weeks (see [43] for detailed information on patient
recruitment and procedures). The study was approved
by the institutional review boards of the participating
hospitals, and informed consent was obtained from all
individual participants included in the study. Data were
collected and processed at The Netherlands Cancer
Institute.
HRQoL questionnaires
We assessed HRQoL at 3 levels: (1) generic (the SF-36
Health Survey) [44]; (2) cancer-specific (the EORTC core
questionnaire (QLQ-C30) [45] and the EORTC prostate
or testicular cancer modules (QLQ-PR25 [46]; QLQ-
TC26) [47]); and (3) cancer survivor-specific (the Impact
of Cancer questionnaire, version 2 (IOCv2) [8, 48]).
Table 1 displays the subscales of these questionnaires.
Additional questions were posed regarding marital sta-
tus, social economic status (SES), race, comorbidity (the
Charlson Index and the International Prognostic Index
(IPI)), work-related problems and problems related to
obtaining health and life insurance, and a home mort-
gage loan [49]. For the TCa survivors only, we also used
four subscales of the Nordic Questionnaire for Monitor-
ing the Age Diverse Workforce (QPSNordic) that assess
work motivation, job and life satisfaction, health and
well-being, and self-efficacy [50]. Respondents were also
asked to complete a 10-item debriefing questionnaire to
identify any questions that were perceived as difficult to
answer, confusing or upsetting, and to report important
survivorship issues that were not (sufficiently) addressed
by the questionnaires. All questionnaires had already
been or were, for purposes of this study, translated using
standard EORTC procedures [51].
Statistical analysis
We performed missing data analyses at both the item and
scale level. A scale score was defined as missing if more
than half of the items in that scale were missing. In all
other cases, we generated a person-specific scale score
based on the mean of the non-missing items [52, 53].
For scales for which scores could not be calculated for
5% or more of respondents, we conducted logistic
regression analysis to determine if missingness was as-
sociated significantly with country/language, age, edu-
cation or marital status.
Descriptive statistics were generated for all measures,
including means, standard deviations and floor and
ceiling effects (20% or more of the scores at the extremes
of the scale [54]). We used Cronbach’s coefficient α [55] to
estimate the reliability (internal consistency) of the ques-
tionnaire scales.
We employed analysis of variance to investigate known
groups validity, i.e., the extent to which the questionnaire
scores are able to discriminate between relevant predefined
subgroups. Grouping variables included age, education,
marital status, disease site (testicular versus prostate) and
comorbidity. A sample size of 120 is sufficient to detect ef-
fect size differences of .25 in a 2-group design and .30 in a
3-group design with a power of .80 and an α .05. An effect
size of .25 is the equivalent of a one-quarter standard devi-
ation difference between groups in mean scores. An effect
size of 0.2 is interpreted as a small difference, 0.5 as a
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Table 1 Questionnaire descriptive statistics and internal consistency reliability estimates for the prostate and testicular cancer
survivor subsamples
PCa Survivors TCa Survivors
Questionnaire scales N M SD % floor/ ceiling Cronbach’sα N M SD % floor/ ceiling Cronbach’s α
SF-36
Physical Functioning 112 73 27 0.93 124 92 15 52c 0.91
Role-Physical 113 61 44 50c 0.91 125 89 26 77c 0.86
Bodily Pain 116 68 26 26c 0.91 126 85 21 56c 0.93
General Health 116 64 20 0.77 125 74 21 0.80
Vitality 114 64 20 0.82 123 66 19 0.82
Social Functioning 116 79 23 38c 0.86 126 84 22 54c 0.81
Role-Emotional 112 74 40 67c 0.88 126 90 24 80c 0.68
Mental Health 113 75 17 0.80 123 79 15 0.83
IOCv2
Altruism/empathy 115 3.3 0.7 0.77 125 3.5 0.8 0.77
Health awareness scale 114 3.1 0.9 0.74 125 3.4 0.8 0.71
Meaning of cancer scalea 112 2.6 0.8 0.85 110 2.8 0.8 0.82
Positive self-evaluation 115 3.3 0.7 0.64 126 3.5 0.8 0.69
Positive Impact Score 115 3.1 0.5 0.82 126 3.3 0.6 0.87
Appearance concerns 114 1.8 0.7 25f 0.73 124 1.9 0.9 33f 0.83
Body change concerns 115 2.6 1.0 0.81 124 2.2 0.9 0.77
Life interferences 115 2.1 0.7 0.75 126 1.8 0.8 21f 0.85
Worry 115 2.4 0.9 0.90 125 2.4 0.9 0.90
Negative Impact Score 115 2.2 0.7 0.93 126 2.1 0.7 0.94
Employment concernsb 132 2.7 1.1 0.63 111 2.1 0.9 23f 0.74
Relationship/not partnered concerns 25 2.3 0.9 0.82 24 2.2 1.1 25f 0.85
Relationship/partnered concerns 92 1.8 0.6 22f 0.52 102 1.5 0.6 39f 0.62
QLQ-C30
Global health status/QoL 112 69 20 0.96 124 79 19 22c 0.92
Physical Function 113 84 18 30c 0.83 126 95 12 68c 0.82
Role Function 114 85 24 61c 0.90 126 94 17 84c 0.93
Emotional Function 113 85 18 40c 0.84 124 86 17 39c 0.84
Cognitive Function 114 83 21 44c 0.73 124 91 16 66c 0.61
Social Function 114 88 20 61c 0.78 124 94 16 82c 0.86
Fatigue 114 22 21 28f 0.84 126 21 21 33f 0.85
Nausea/vomitingc 114 1 5 91f −0.04 126 2 6 87f –
Pain 114 18 25 53f 0.89 126 12 20 63f 0.85
Dyspnoead 114 15 22 63f – 125 9 18 75f –
Insomniad 113 18 29 65f – 126 13 22 68f –
Appetite lossd 113 5 17 91f – 126 4 14 89f –
Constipationd 114 11 21 75f – 120 5 14 87f –
Diarrhoead 113 7 18 83f – 124 6 17 85f –
Financial problemsd 114 5 18 90f – 123 8 21 86f –
QLQ-PR25
Sexual activity 112 26 25 32 f 0.67 – – – – –
Sexual functioning 43 51 20 0.41 – – – – –
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moderate difference, and 0.8 as a large difference [56].
The a priori hypotheses were that those who were
younger, with a higher education, with a partner, and
with fewer comorbid conditions (as assessed by self-
report) would generally report better HRQoL. We also
hypothesized that TCa survivors would report better
HRQoL than PCa survivors, due to their younger age
and to the relatively transient nature of some of the
treatment effects.
Results
Sample accrual and response rate
Data collection took place between February 2010 and
June 2012. Of the 366 survivors invited to participate in
the study, 242 (66%) agreed to do so. The response rate
in the PCa survivor group was somewhat higher than in
the TCa group (69% vs 64%). See van Leeuwen et al. [43]
for more details on patients recruitment. Table 2 reports
the patient background characteristics.
Completeness of the data
With a few exceptions, the percentage of missing item
values was low, ranging from 0 to 7%. Although TCa sur-
vivors had to complete more items, items were missing
less frequently in the TCa sample than in the PCa sample.
The most important exceptions were the missing re-
sponses on the items of the Sexual Functioning scale of
the QLQ-PR25. Among the PCa survivors who had indi-
cated that they were sexually active during the past week,
missing responses varied between 37 and 43%. Other
QLQ-PR25 items with relatively high percentages of miss-
ing responses were one item from the Urinary Symptom
scale (posed following an item which was only applicable
to patients wearing incontinence material; 14%), the Sex-
ual Activity scale (10%), and items from the Treatment-
Related Symptom scale that were related to hormonal
treatment (6 to 8%). For the IOCv2, the highest percentage
of missing responses was for the Relationship Concerns
(both partnered and not partnered) scales (7 to 23%).
Table 1 Questionnaire descriptive statistics and internal consistency reliability estimates for the prostate and testicular cancer
survivor subsamples (Continued)
Urinary problems 115 22 20 0.89 – – – – –
Incontinence aid problemsd 49 29 34 49 f – – – – – –
Bowel problems 108 8 14 52 f 0.79 – – – – –
Treatment related symptoms 112 13 12 0.45 – – – – –
QLQ-TC26
Satisfaction with care – – – – – 111 80 28 52c 0.85
Future perspective – – – – – 125 77 24 36c 0.56
Communication – – – – – 125 76 25 34c 0.53
Sexual activity – – – – – 121 60 27 0.77
Sexual enjoyment – – – – – 116 76 25 38c 0.77
Satisfaction with testicular implantd – – – – – 35 55 37 31c –
Treatment side effects – – – – – 125 11 12 28f 0.63
Job problems – – – – – 125 15 26 66f 0.82
Sexual problems – – – – – 115 13 22 65f 0.59
Family problemsd – – – – – 125 15 28 70f –
Infertilityd – – – – – 123 24 34 58f –
Body Imaged – – – – – 125 18 28 62f –
QPSNordic
Work Motivation – – – – – 113 3.8 0.7 0.42
Job and life satisfaction – – – – – 113 3.9 0.8 0.71
Work ability – – – – – 113 3.8 0.8 0.82
Self-efficacy – – – – – 113 4.4 0.8 40c 0.83
Scale range for the SF-36, QLQ-C30, QLQ-PR25 and QLQ-TC26 is from 0 to 100. The IOCv2 and QPS Nordic scale range from 1 to 5. For the function scales and
global health scale of the EORTC-QLQC30 and its modules a higher score represents a better level of functioning. For the symptom oriented scales and items
higher scores indicate a higher level of symptoms; Percentage floor or ceiling effects are only reported when they exceed 20%.; TCa testicular cancer survivors,
PCa prostate cancer survivors, N number of participants, M mean, SD standard deviation, c ceiling, f floor
aDue to a mistake in the Norwegian version of the IOCv2 14 respondents skipped more than half of the items of this scale
bN is higher than the number of respondents who were actually employed, since the item was also completed by some participants who were retired
cReliability of the NV scale could not be calculated do to the very low prevalence of nausea and the absence of vomiting in the TCa sample
dSingle item scales
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There were four scales for which we could not calcu-
late the scale scores for more than 5% of the PCa
sample: the QLQ-PR25 Sexual Functioning and Bowel
Symptom scales (37 and 7%, respectively); and the
IOCv2 Relationship Concern scales (both partnered
and not partnered) (20 and 8%, respectively). Missing
responses on the QLQ-PR25 Sexual Functioning scale
were associated significantly with (older) age. Belgian
participants were significantly more likely to skip items
of the Bowel Symptom scale. No other significant asso-
ciations were observed in the PCa sample between item
missingness and sociodemographic variables.
In the TCa sample, missing responses were primarily
observed for those items that were associated with con-
tingency questions (e.g., the IOCv2 items applicable
only for sub-groups of respondents, such as those with
a partner). With the exception of the item “I wonder
how to tell a potential spouse, partner, boyfriend or girl-
friend that I have had cancer” (skipped by 18% of the
respondents), missing item responses for those scales var-
ied between 4 and 8%. Items of the QLQ-TC26 that were
related to satisfaction with care (14%) and to sexuality (6
to 10%) were also skipped more frequently.
There were four scales for which scores could not be
calculated for more than 5% of the TCa sample: the
IOCv2 Relationship Concerns scale (not partnered;
13%); and Satisfaction with Care scale (12%), the Sexual
Enjoyment (5%), and Sexual Problems (6%) of the QLQ-
TC26. The Italian patients were most likely to complete
the Satisfaction with Care and the Sexual Problems
scale. Items from the Sexual Enjoyment and Sexual
Problems scales were most frequently left unanswered
by respondents without a partner. Dutch respondents
also skipped more items of the Sexual problems scale.
Debriefing questionnaire
Sixty-five survivors (of whom 27 were from the TCa
sample) reported an issue with one or more of the ques-
tions or left a general comment for the doctors or re-
searchers on the debriefing questionnaire. Twelve
survivors stated that they had difficulties distinguishing
cancer-related problems from those due to aging and
other conditions. Seven survivors reported they found
the questions regarding sexual problems too personal,
too confusing and/or too difficult to answer. Two
Table 2 Sample characteristics of the prostate and testicular
cancer survivor samples
PCa survivors
(N = 116)
TCa survivors
(N = 126)
Age
Mean ± SD (years) 75.0 (5.8) 43.1 (8.8)
Civil status (%)
married/living with partner 92 (79%) 85 (67%)
widower 11 (10%) –
divorced/separated 8 (7%) 7 (6%)
in relationship living apart – 15 (12%)
never been married/living together 4 (3%)a 16 (13%)
Education (%)
university 23 (20%) 42 (33%)
vocational education 46 (40%) 50 (40%)
high school 24 (21%) 26 (21%)
primary school 21 (18%) 6 (5%)
Work status (%)
fulltime (≥ 32 h per week) 2 (2%) 92 (73%)
part-time (< 32 h per week) 1 (1%) 13 (10%)
irregular hours 1 (1%) –
retired 111 (96%) 6 (5%)
unemployed – 2 (2%)
incapable of work 1 (1%) 9 (7%)
household – 2 (2%)
Country (%)
The Netherlands 44 (38%) 37 (29%)
Belgium 37 (32%) –
United Kingdom – 29 (23%)
Norway – 23 (18%)
France 25 (22%) –
Italy 10 (9%) 37 (29%)
Time since treatment allocation
Mean (SD) (years) 13.0 (2.1) –
Time since treatment evaluation
Mean (SD) (years) – 11.9 (3.8)
Treatment allocation (%)
prostatomectomy and wait and see 53 (46%) –
prostatomectomy and radiation 61 (53%) –
four cycles/ five days – 27 (21%)
four cycles/ three days – 23 (18%)
three cycles/ five days – 53 (42%)b
three cycles/ three days – 23 (18)
Co-morbid disorders (%)
0 22 (19%) 58 (46%)
Table 2 Sample characteristics of the prostate and testicular
cancer survivor samples (Continued)
1 22 (19%) 36 (29%)
2 29 (25%) 20 (16%)
3 or more 35 (30%) 8 (6%)
aTotals which do not add up to 100% are caused by missing data. bMost
patients recruited outside the trial were treated with this regimen. N number
of participants, SD Standard deviation
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survivors found the questions regarding incontinence
too confusing or too difficult. Three survivors found that
some questions were more related to the treatment and
diagnosis phase. Further, 18 survivors reported missing
issues, of which dealing with sexual problems (6) and
long-term side effects of treatment (2) were the most
often mentioned. Finally, four survivors over 80 years of
age considered some questions redundant for survivors
of their age (e.g. questions regarding work, feeling old,
and future perspective).
Scale level descriptive statistics and reliability
Scale level descriptive statistics and reliability estimates
are presented in Table 1.
The SF-36
Ceiling effects were observed for four of the eight SF-36
scales in the PCa sample, and for five scales in the TCa
sample. The role functioning scales exhibited the most
serious ceiling effects. Cronbach’s coefficient α varied
between .68 and .93 (see Table 1).
The EORTC QLQ-C30
All scales of the EORTC QLQ-C30 exhibited ceiling or
floor effects in both the PCa and the TCa, samples, with
the exception of the Global quality of life scale in the
PCa sample. Cronbach’s α coefficients varied between
.70 and .96, with the exception of the Emesis scale,
which was very low in the PCa sample (0.04) and could
not be calculated in the TCa sample due to the ex-
tremely low prevalence rates for these symptoms in
these survivor samples (see Table 1).
The IOCv2
The Relation Concerns (partnered) and the Appearance
Concerns scales exhibited floor effects in both samples.
In the TCa sample, the Life Interferences, Employment
Concerns and Relationship Concerns (not partnered)
scales exhibited significant floor effects. Cronbach’s α co-
efficients ranged from .52 to .94. Three of the 11 IOCv2
scales had a Cronbach’s α lower than .70 in the PCa
sample (Positive self-evaluation (.64), Employment con-
cerns (.63) and Relationship partnered concerns (.52)),
and two scales had a Cronbach’s α coefficient lower than
.70 in the TCa sample (Positive self-evaluation (.69) and
Relationship partnered concerns (.62); see Table 1).
The QLQ-PR25
Three of the six scales of the QLQ-PR25 exhibited a
floor effect. Cronbach’s α coefficient varied between .41
and .89, with three scales below .70 (Sexual activity (.67),
Treatment related symptoms (.45) and Sexual function-
ing (.41)) (see Table 1).
The QLQ-TC26
Except for Sexual Activity, all scales of the QLQ-TC26
showed substantial floor and ceiling effects. Cronbach’s
α coefficient varied between .53 and .89, with four scales
scoring below .70. The Cronbach’s α for Future perspec-
tive was .56, for Communication .53, for Treatment side
effects .63, and for Sexual Problems .59 (see Table 1).
The QPSNordic
Only the Self-Efficacy scale of the QPSNordic showed a
substantial ceiling effect. Cronbach’s α coefficient varied
between .42 and .83, with only Work motivation being
below .70 (see Table 1).
Tests of known-groups validity
Age
In the PCa sample, (older) age was most strongly associ-
ated with physical health problems, although there was
also a strong association with cognitive functioning and
sexual activity level. Effects sizes ranged from 0.32 to 1.05.
The association between age and HRQoL was much less
pronounced in the TCa than in the PCa sample. However,
the younger men in the TCa sample reported significantly
more mental health problems (effect size (ES) .37–.58),
were more sexually active (ES .17–.66) and worried signifi-
cantly more about their fertility (ES.70–1.07) than older
men (see Tables 3 and 4).
Education
In the PCa sample, higher education was significantly
associated with better physical and mental health, less
appearance concerns and life interferences (effect sizes
ranging from .25 to greater than 1). There was only a
weak association between education level and HRQoL
observed in the TCa sample (see Tables 3 and 4).
Marital status
Marital status was not significantly associated with
HRQoL in the PCa sample. In contrast, in the TCa sam-
ple, single men reported consistently and significantly
worse HRQoL than partnered men across almost all scales
of all questionnaires, with effect sizes ranging from .48 to
.93 (see Tables 3 and 4).
Comorbidity
In both the PCa and the TCa samples, men with two or
more comorbid conditions (or one or more in the TCa
sample) reported significantly and consistently poorer
HRQoL, as measured by all questionnaires, than those
without comorbid conditions. Effect sizes (ES) ranged
from .36 to .86 (see Tables 3 and 4).
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PCa versus TCa sample
As hypothesized, the TCa sample reported significantly
better physical health, social and cognitive functioning,
and fewer symptoms than the PCa sample, with effect
sizes ranging from .29 to .82. No significant group differ-
ences were observed for fatigue, social functioning, mental
health, or for most of the symptom scales of the QLQ-
C30 (see Table 5).
Discussion
In this study we have assessed the psychometric perform-
ance of a number of widely used HRQoL questionnaires
Table 3 Known group validity testing: Effect sizes for the differences within the prostate cancer sample between subgroups formed
on the basis of comorbidity status, age, education and marital status
PCa survivors
Co-morbidities Age Education Marital status
0–1 comorbiditiesa 2 or more
co-morbidities
Younger
than 70a
70–80 80 and
older
Universitya College and
high school
Primary
school only
Singlea Partner
SF36: Physical Functioning −0.60 −0.72 −1.05 −0.39 −0.67 0.22
SF36: Role-Physical −0.66 −0.66 −0.84 −0.43 −0.44 −0.07
SF36: Bodily Pain −0.86 −0.32 −0.55 −0.50 −0.53 −0.03
SF36: General Health −0.48 −0.42 −0.73 −0.42 −0.70 0.30
SF36: Vitality −0.57 −0.40 −0.58 −0.54 −0.73 0.03
SF36: Social Functioning −0.47 −0.30 −0.41 −0.38 −0.56 0.27
SF36: Role-Emotional −0.44 −0.46 −0.61 −0.56 −0.58 0.25
SF36: Mental Health −0.49 −0.29 −0.65 −0.47 −1.02 0.26
QLQ-C30: Global health status/QoL −0.61 −0.51 −0.85 −0.51 −0.79 −0.01
QLQ-C30: Physical Function −0.58 −0.68 −0.95 −0.34 −0.63 0.12
QLQ-C30: Role Function −0.52 −0.50 −0.55 −0.31 −0.59 −0.05
QLQ-C30: Emotional Function −0.51 −0.27 −0.35 −0.35 −1.01 0.27
QLQ-C30: Cognitive Function −0.49 −0.41 −0.87 −0.30 −0.48 0.03
QLQ-C30: Social Function −0.58 −0.15 −0.29 −0.19 −0.53 0.37
QLQ-C30: Fatigue −0.57 −0.23 −0.25 −0.53 −0.86 0.02
QLQ-C30: Nausea / vomiting −0.14 0.07 −0.27 −0.10 −0.55 0.21
QLQ-C30: Pain −0.58 −0.34 −0.40 −0.32 −0.27 −0.08
QLQ-C30: Dyspnoea −0.54 −0.30 −0.60 −0.16 −0.65 0.34
QLQ-C30: Insomnia −0.34 −0.39 −0.43 −0.32 −0.50 0.20
QLQ-C30: Appetite loss −0.05 −0.23 0.29 −0.14 −0.63 0.09
QLQ-C30: Constipation −0.50 −0.03 −0.57 −0.05 −0.66 0.04
QLQ-C30: Diarrhoea −0.23 0.32 0.75 −0.07 0.16 0.32
QLQ-C30: Financial problems 0.12 0.63 0.35 −0.16 −0.21 0.36
IOC: Appearance concerns −0.46 −0.38 −0.18 −0.25 −0.94 0.35
IOC: Body change concerns −0.55 −0.41 −0.18 −0.42 −0.55 0.09
IOC: Life interferences −0.59 −0.16 −0.28 −0.54 −0.84 0.16
IOC: Worry −0.46 0.03 0.05 −0.05 −0.41 0.19
IOC: Negative Impact Scale −0.62 −0.19 −0.15 −0.35 −0.73 0.21
PR25: Sexual activity −0.12 −0.32 −0.75 0.05 −0.18 0.38
PR25: Sexual functioning −0.51 −0.63 −0.35 0.25 0.22 0.23
PR25: Urinary problems −0.50 −0.37 −0.60 −0.47 −0.67 0.27
PR25: Incontinence aid problems −0.36 −0.74 −0.27 −0.43 −0.71 −0.30
PR25: Bowel problems −0.39 −0.30 −0.51 −0.02 −0.61 0.16
PR25: Treatment related symptoms −0.34 −0.27 −0.51 −0.54 −0.44 −0.01
Effect sizes are displayed in bold in those cases where the known groups differed significantly (p ≤ .05). A positive effect size reflects better HRQoL
than the reference group, and a negative effect size reflects worse HRQoL than the reference group. areference group. PCa = prostate cancer
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Table 4 Known group validity testing: effect sizes (ES) of the differences within the testicular cancer sample between the known
groups based on comorbidity status, age, education and marital status
TCa survivors
Co-morbidities Age Education Marital status
0 comorbiditiesa 1 or more
co-morbidities
Younger
than 40a
40–50 50 and
older
Universitya Higher
education
High school
or less
Singlea Partner
SF36: Physical Functioning −0.66 −0.33 −0.41 −0.11 −0.58 0.61
SF36: Role-Physical −0.62 −0.09 −0.12 −0.20 −0.24 0.93
SF36: Bodily Pain −0.84 −0.34 −0.28 0.00 −0.14 0.64
SF36: General Health −0.55 −0.37 −0.21 0.03 −0.16 0.74
SF36: Vitality −0.61 −0.07 −0.13 0.13 −0.10 0.52
SF36: Social Functioning −0.49 −0.10 0.17 −0.18 −0.10 0.93
SF36: Role-Emotional −0.27 0.06 0.07 −0.21 −0.24 0.64
SF36: Mental Health −0.20 0.37 0.58 −0.18 −0.11 0.65
QLQ-C30: Global health status/QoL −0.36 −0.09 0.20 0.01 −0.29 0.67
QLQ-C30: Physical Function −0.69 −0.29 −0.27 0.07 −0.42 0.75
QLQ-C30: Role Function −0.55 −0.19 0.08 0.04 −0.43 0.90
QLQ-C30: Emotional Function −0.48 0.01 0.17 0.04 −0.26 0.86
QLQ-C30: Cognitive Function −0.48 −0.07 −0.30 −0.06 0.08 0.74
QLQ-C30: Social Function −0.47 −0.07 0.12 0.14 0.01 0.66
QLQ-C30: Fatigue −0.81 −0.07 −0.38 0.12 −0.31 0.76
QLQ-C30: Nausea / vomiting −0.40 0.12 0.17 −0.12 −0.25 0.55
QLQ-C30: Pain −0.80 −0.20 −0.19 0.13 −0.13 0.63
QLQ-C30: Dyspnoea −0.45 −0.21 −0.40 0.27 −0.37 0.19
QLQ-C30: Insomnia −0.43 0.15 0.14 −0.03 −0.04 0.73
QLQ-C30: Appetite loss −0.17 0.06 0.10 0.04 −0.33 0.60
QLQ-C30: Constipation −0.24 −0.10 −0.03 0.31 0.06 0.48
QLQ-C30: Diarrhoea −0.03 −0.13 0.04 0.59 0.56 0.15
QLQ-C30: Financial problems −0.37 0.06 −0.40 0.09 −0.12 0.41
IOC: Appearance concerns −0.13 0.19 0.35 0.07 −0.07 0.31
IOC: Body change concerns −0.41 −0.15 −0.32 −0.06 −0.30 0.34
IOC: Life interferences −0.33 −0.01 −0.02 −0.07 −0.14 0.65
IOC: Worry −0.42 −0.06 0.12 0.02 −0.19 0.23
IOC: Negative Impact Scale −0.42 −0.04 0.04 −0.02 −0.25 0.50
TC26: Satisfaction with care −0.23 −0.08 −0.17 0.02 0.03 −0.06
TC26: Future perspective −0.32 0.01 0.07 −0.04 −0.36 0.52
TC26: Communication 0.05 0.16 −0.16 −0.22 −0.04 0.04
TC26: Sexual activity −0.30 −0.17 −0.66 −0.19 −0.13 0.56
TC26: Sexual enjoyment −0.30 0.00 −0.54 −0.15 −0.27 0.57
TC26: Satisfaction with testicular implant −0.36 0.76 0.50 −0.09 −0.78 0.26
TC26: Treatment side effects −0.57 −0.10 −0.08 −0.04 −0.14 0.52
TC26: Job problems −0.34 −0.01 0.15 −0.02 −0.31 0.48
TC26: Family problems −0.17 −0.05 0.07 0.18 −0.18 0.09
TC26: Infertility 0.06 0.70 1.07 0.14 0.04 0.23
TC26: Body Image −0.26 0.31 0.14 0.36 0.01 0.54
TC26: Sexual problems −0.38 0.17 −0.23 −0.19 −0.06 0.36
QPS: Work Motivation −0.28 −0.05 0.49 −0.03 0.03 0.49
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for specific use in cancer survivorship research. The
response rate was quite reasonable (66%), given that these
were long-term survivors (on average, more than 10 years
post-diagnosis and treatment). Our response rate is com-
parable to that of many mail surveys in health research
[57, 58]. The questionnaires were well received by these
survivors.
Psychometric performance of the questionnaires
Missing items were particularly an issue for the scales
assessing employment and relationship concerns in the
IOCv2, and the scales of the cancer-specific modules
assessing sexuality, bowel functioning, complaints re-
lated to hormonal treatment (for PCa) and treatment
satisfaction. This problem with missing item responses
was often related to the sensitive nature of the ques-
tions or to branching and skip patterns in the question-
naire (i.e., use of contingency questions). The high level
of missingness in the scales assessing sexual problems
and functioning are particularly noteworthy, and this
could lead to an underestimation of the prevalence of
these problems in these survivor populations. Missing
responses to sensitive questions (e.g. sexuality) are
common and quite difficult to resolve, although there
are studies suggesting that response rates could be im-
proved by using online computer administration [59].
Further, our findings suggest that branching questions
should be used judiciously to minimize respondent
confusion.
The questionnaires assessing symptoms and physical
functioning all showed floor and ceiling effects, particu-
larly in the younger TCa survivors. This can be expected
in groups of survivors where the self-reported HRQoL
is similar to that of the healthy, general population.
Moreover, short-term, treatment-induced symptoms
like nausea and vomiting or acute hair loss often are no
longer relevant in these long-term survivors. These floor
and ceiling effects are due, at least in part, to the fact that
the SF-36 and the EORTC QLQ-C30 and its condition-
specific modules were not developed for or intended to
discriminate between individuals who are at the higher
end of the health spectrum (e.g., those with moderate to
excellent health). A number of studies have previously re-
ported that the SF-36 and the EORTC QLQ-C30 exhibit
significant ceiling and floor effects when used in general
population surveys [60–63].
In general, the internal consistency reliability of the
questionnaires was acceptable for group level compari-
sons. Problems were observed with several scales of the
PR25 and of the TC26, two scales of the IOCv2, and
Table 4 Known group validity testing: effect sizes (ES) of the differences within the testicular cancer sample between the known
groups based on comorbidity status, age, education and marital status (Continued)
QPS: Job and life satisfaction −0.21 −0.01 0.21 −0.03 0.05 0.51
QPS: Work ability −0.37 −0.23 −0.50 −0.26 −0.37 0.59
QPS: Self-efficacy −0.13 −0.41 −0.37 −0.28 −0.27 −0.27
Effect sizes are displayed in bold in those cases where the known groups differed significantly (p ≤ .05). TCa testicular cancer
A positive effect size reflects better HRQoL than the reference group, and a negative effect size reflects worse HRQoL than the reference group
areference group
Table 5 Known group validity testing: effect sizes of the
differences between the prostate and the testicular cancer
samples
PCa versus TCa survivors
SF36: Physical Functioning 0.82
SF36: Role-Physical 0.73
SF36: Bodily Pain 0.69
SF36: General Health 0.51
SF36: Vitality 0.10
SF36: Social Functioning 0.23
SF36: Role-Emotional 0.48
SF36: Mental Health 0.25
QLQ-C30: Global health status/QoL 0.49
QLQ-C30: Physical Function 0.67
QLQ-C30: Role Function 0.44
QLQ-C30: Emotional Function 0.01
QLQ-C30: Cognitive Function 0.40
QLQ-C30: Social Function 0.33
QLQ-C30: Fatigue 0.06
QLQ-C30: Nausea / vomiting −0.16
QLQ-C30: Pain 0.30
QLQ-C30: Dyspnoea 0.29
QLQ-C30: Insomnia 0.18
QLQ-C30: Appetite loss 0.01
QLQ-C30: Constipation 0.31
QLQ-C30: Diarrhoea 0.05
QLQ-C30: Financial problems −0.02
IOC: Appearance concerns −0.03
IOC: Body change concerns 0.38
IOC: Life interferences 0.45
IOC: Worry −0.01
IOC: Negative Impact Scale 0.21
Effect sizes are displayed in bold in those cases where the known groups differed
significantly (p ≤ .05). PCa prostate cancer, TCa testicular cancer. A positive effect
size reflects better HRQoL in TCa survivors
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one scale of the QPSNordic. In the case of the
treatment-related symptom scales, this often reflected
the low prevalence of certain symptoms among long-
term survivors, as has also been reported by O’Leary in
a population-based sample of prostate cancer survivors
[9]. However, suboptimal reliability has also been re-
ported for some scales even during the period of active
treatment [46]. The problematic internal consistency of
the positive self-evaluation scale of the IOCv2 was also
observed in an Italian validation study [64] and in a
French validation study the health awareness scale ap-
peared problematic [65]. However, in a Dutch valid-
ation sample none of these problems were observed
[66].
The HRQoL questionnaires were able to discriminate
well between patients with and without comorbid condi-
tions. Comorbid disorders might affect self-reported
functioning more strongly than any residual effect from
cancer or its treatment [61]. In the other known-group
comparisons there was not always sufficient power to
reach statistical significance. Nevertheless, the trends ob-
served in the known groups were compatible with our
hypotheses, except for the higher levels of mental health
problems reported by the younger TCa survivors. This
latter finding is similar to results reported in studies of
younger breast cancer survivors [67–70]. The recent
study of Drummond et al. shows that, with larger sample
sizes, the EORTC QLQ-C30 and the QLQ-PR25 are able
to discriminate between different initial treatment mo-
dalities in long-term prostate cancer survivors [71].
Recommendations for assessing HRQOL in cancer survivors
Despite their limitations, we consider both the SF-36 and
the EORTC QLQ-C30 to be sufficiently robust psycho-
metrically to be employed in cancer survivorship studies.
Although they may not be able to differentiate clearly
between survivors at higher levels of functioning and
lower levels of symptom burden, they can identify func-
tional health issues and relevant symptom levels that may
require attention by health care providers.
The IOCv2 is a questionnaire which addresses the
unique concerns related to the cancer experience that are
not captured by the more generic HRQoL questionnaires
[48]. Most of the previous studies using the IOCv2 have
been carried out in mixed samples and samples with
women only e.g. [66, 72], which makes their results diffi-
cult to compare with ours. In particular, we know that
women report more extreme impacts of cancer and its
treatment (both positive and negative) on their lives than
men [72, 73]. We can best compare our results with two
previous studies of male hematological survivors and with
the Norwegian validation study [66, 73, 74]. Compared to
long-term male lymphoma survivors, survivors in our
sample reported less extreme negative or positive impacts
of having had cancer [74]. Similar to what has been re-
ported previously by Oerlemans et al. [66], the men in
our sample reported few appearance concerns, and, like
Dahl et al. [73], we found that TCa survivors were less
negatively impacted by cancer than PCa survivors.
These differences in outcomes on the IOCv2 underline
the relevance of this questionnaire for detecting differ-
ences between survivor groups in how cancer and its
treatment have affected their lives.
The selected scales from the QPSNordic can be particu-
larly useful in assessing cancer survivors’ work experience.
Ours as well as previous studies (e.g. [72, 75, 76]) indicate
that a significant minority of cancer survivors experience
work-related changes after being diagnosed with and
treated for cancer. Particularly survivors with mental and
physical health problems are vulnerable to work-related
problems. Work ability levels observed in our sample of
TCa survivors were comparable to that of mid-term
Norwegian breast, TCa, and PCa cancer survivors.
Gudbergsson et al. reported that the work ability in these
cancer survivors was significantly worse than that of an
age and gender matched control group [77].
The Patient-Reported Outcomes Measurement Infor-
mation System (PROMIS) initiative [78] and the EORTC
Quality of Life Group (EORTC QLG) Computer-Adaptive
Testing project [79, 80] are currently developing HRQoL
instruments based on item response theory which, among
other things, will make it possible to discriminate better
between individuals who score at the extremes of the
health continuum. Also, the EORTC QLG is currently de-
veloping an HRQoL assessment strategy specifically for
disease-free cancer survivors, focusing on longer-term
physical effects of cancer and its treatment, psychological
aspects of survivorship, and important issues such as fear
of recurrence and health awareness, and excluding acute
treatment related symptoms.
Generalizability of our findings
Even though our response rate is quite reasonable for this
type of long-term follow-up study, we cannot rule out the
possibility of some degree of selection bias in our sample.
It could be that the non-respondents had fewer physical
and psychosocial health issues (and thus were less moti-
vated to participate in the study) than those who partici-
pated. It may also be that non-respondents did not want
to be confronted with their earlier cancer experience.
Unfortunately, we do not have any information about the
actual reasons for not participating in the study, and thus
the nature of any bias, if present, remains unclear.
As our study sample was restricted to male survivors
only, we cannot generalize our findings to the larger
population of cancer survivors. Additional studies are
needed that include significant numbers of female can-
cer survivors. There is, for example, some evidence that
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women report higher levels of symptom burden and
functional impairment than men. Problems observed in
the current study with regard to floor and ceiling ef-
fects may be less pronounced in studies of female survi-
vors or with mixed samples with regard to sex [62].
Additionally, our study sample was composed primarily
of participants in randomized clinical trials. Patients
treated in the context of clinical trials often are not en-
tirely representative of the patient population encountered
in clinical practice. Trial patients are often younger and
have fewer comorbid conditions than non-trial patients
[81, 82]. Also, patients treated in the context of a trial may
receive more consistent and higher quality care than those
treated outside of a trial context [83]. While this may
affect the actual prevalence of symptoms and functional
limitations reported by long-term survivors, it is less rele-
vant for evaluating the psychometric properties of HRQoL
questionnaires, which was the focus of our study. Also,
given the relatively long period of time since diagnosis and
active treatment, the effect of having been treated in the
context of a clinical trial probably has less impact on the
generalizability of findings than might be the case in a
study with a shorter follow-up [81, 82]. In any case, fur-
ther studies are needed that investigate the performance
of these and other HRQoL questionnaires when used with
the broader clinic populations.
Conclusions
In general, the questionnaires evaluated in this study were
found to be reliable and valid when used among male
cancer survivors in various European settings. Several
international initiatives are developing both computer-
adaptive and survivorship-specific patient-reported out-
come measures. These newer measures promise greater
measurement precision and specificity. However, until
they are sufficiently mature for general use, our results in-
dicate that both the SF-36, the EORTC QLQ-C30 (and its
modules), the IOCv2 and the QPSNordic are, within
limits, useful tools for assessing the HRQoL of long term
cancer survivors.
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